NOTE TO THE FILE
SERIAL NUMBER: 88383413
DATE: 06/24/2019
NAME: kcrennan
NOTE:
Searched:
Lexis/Nexis
OneLook
Wikipedia
Acronym Finder Protest evidence reviewed
Other:Checked:
Geographic significance
Surname
Translation
ID with ID/CLASS mailboxChecked list of approved Canadian attorneys and agents
Discussed file with
Attorney/Applicant via:
phone Left message with
X email Attorney/ApplicantRequested Law Library search Issued Examiner’s Amendment
for: and entered changes in TRADEUPSPRINT DO NOT PRINT Added design code in TRADEUPS
Description of the mark
Translation statement Re-imaged standard character
drawing
Negative translation statement
Consent of living individual Contacted TM MADRID ID/CLASS
about misclassified definite ID
Changed TRADEUPS to:From: Terry Dixon [mailto:terry.a.dixon@gsk.com]
Sent: Monday, June 24, 2019 2:19 PM
To: Crennan, Kevin <Kevin.Crennan@USPTO.GOV>
Subject: 82774066: U.S. Trademark Application Serial No. 88383413 OPTIZORB (Response Requested by June 27th)
Dear Mr. Crennan,
My apologies for any confusion. Yes, I confirm that the mark as it appears in the foreign registration (EUTM Reg. No. 004767992) is in standard characters or their equivalent. If possible, please amend the application by an Examiner’s Amendment to reflect this fact.
Respectfully submitted,
Terence A. Dixon
Assistant General Counsel
Legal Brand Protection
GSK
5 Crescent Drive, Philadelphia, PA 19112, United States
Email terry.a.dixon@gsk.com
Mobile +1 484 885 9127
gsk.com | Twitter | YouTube | Facebook | Flickr
From: Crennan, Kevin <Kevin.Crennan@USPTO.GOV>
Sent: Saturday, June 22, 2019 4:19 PM
To: TM Trademarks <trademarks@gsk.com>
Subject: U.S. Trademark Application Serial No. 88383413 OPTIZORB (Response Requested by June 27th)
EXTERNAL
Hello Mr. Dixon,
I’ve reviewed the above trademark application for registration. Before I can approve it for publication for opposition, however, can you please clarify that the mark as it appears in the foreign registration is in standard characters or their equivalent? You indicated in the application that the mark in the foreign registration is not in standard character or their equivalent, thereby creating an ambiguity.
Please let me know your thoughts by June 27th, if possible.
Thanks,
/KGC/
Kevin G. Crennan
Trademark Examining Attorney
Law Office 113
United States Patent and Trademark Office
(571) 272-7949
GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.